AGA
Clinical trials for AGA explained in plain language.
Never miss a new study
Get alerted when new AGA trials appear
Sign up with your email to follow new studies for AGA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could help women regrow hair – but It's not a cure
Disease control OngoingThis study tests an oral drug called VDPHL01 in 552 women aged 18–65 with mild to moderate hereditary hair loss. Participants take a pill once or twice daily for about 13 months. The goal is to see if it increases hair count and if women feel their hair looks better. It's a place…
Matched conditions: AGA
Phase 3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New pill could help men keep their hair
Disease control OngoingThis Phase 3 trial tests an oral drug called VDPHL01 in 480 men aged 18-65 with mild to moderate male pattern baldness. The study is double-blind and placebo-controlled, lasting about 13 months. Researchers will measure hair counts and patient satisfaction at 6 months to see if t…
Matched conditions: AGA
Phase 3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New hair loss pill shows promise in early trial
Disease control OngoingThis Phase 2 study tests an investigational oral drug called VDPHL01 in 70 adults with mild to moderate pattern baldness. Participants take a tablet once or twice daily for 12 months. Researchers will measure changes in hair count and ask participants about perceived benefit. The…
Matched conditions: AGA
Phase 2 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New pill could help men regrow hair
Disease control OngoingThis study tests an experimental oral drug called VDPHL01 for male pattern baldness (androgenetic alopecia). About 480 men aged 18 to 65 with mild to moderate hair loss will take either the drug or a placebo for 6 months, then all will receive the active drug for another 6 months…
Matched conditions: AGA
Phase 2/3 • Sponsor: Veradermics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC